Analyst Actions: Nxstage Medical, Western Refining, Kenexa
<<   May/2008   >>
Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

Arts
Movies
Humor
Television
Music

Business
Internet
Finance
Jobs
Investing
Economy

Computers
Software
Hardware
World
Mobile

Games
Video Games
RPGs

Health
Fitness
Medicine
Alternative

Home
Consumers
Cooking

Recreation
Travel
Food
Outdoors

Reference
Psychology
Science
Education

Regional
US
Canada
Europe

Science
NSF
Space
Technology

Society
People
Religion

Sports
Baseball
Soccer
Basketball
 
13/May/2008 11:31AM

WILLIAM BLAIR CUTS NXSTAGE MEDICAL TO MARKET PERFORM FROM OUTPERFORM

William Blair analyst Ben Andrew says his investment thesis for Nxstage Medical (NXTM) for the next 6-12 months has shifted from one driven by significant growth in the company's daily chronic and home hemodialysis franchise to one more balanced by growth in all three of its businesses. He believes it appropriate to fully reevaluate his position.

Andrew notes $31 million first quarter revenue exceeded his target by $1 million, however, chronic care sales came in at $10.5 million, $800,000 below his estimate, with net patient adds of 258, 77 below his estimate.

He adjusts his model to reflect management's guidance and his belief that business model will develop slower than originally expected. He sees $1.38 2008 loss and $0.87 2009 loss.

CARIS DOWNGRADES WESTERN REFINING TO SELL FROM AVERAGE

Caris analyst Ann Kohler says Western Refining's (WNR) solid performance from retail and wholesale businesses was overwhelmed by skyrocketing operations costs at both Four Corners and Yorktown refinery, poor margin capture due to systems reliance of sweet crude, and high production of gasoline.

More importantly, noticeably absent from its earnings release was management plan to address the company's impending breech of its debt covenant. In a 10-Q filing, Western Refining said if margins continue to deteriorate, it may be unable to comply with financial covenants. Kohler thinks this inability will heighten investor concern pertaining to the company's ability to continue as a going concern.

As such, she downgrades the stock to sell and slashes her 9 price target to 2.75.

NEEDHAM UPS ESTIMATES FOR KENEXA

Needham analyst Richard Davis says Kenexa's (KNXA) first quarter results were good given an economic deceleration that's brought multiple compression and accelerated consolidation to human resource management system industry.

Davis raises $1.40 2008 EPS estimate to $1.50, and $1.75 for 2009 to $1.85. He notes the company was the first to seize on stagnation of once-great PSFT; it attacked this market with a busines model that delivered consistent growth.

He also notes he was the first to highlight the eventual integration effort from a well-executed acquisition binge. He doubts this effort will be very traumatic to margins, but until he gets a bit more clarity on how KNXA plans to grow, he maintains hold.




Recent news in category
Stocks End Mostly Higher
Why American Savers Have Drawn the Short Straw
Where Homes Are Selling Fastest

Global recent news
Curried Zucchini Soup Recipe
Scottish Executive Launches More AntiSectarian Material for Schools
Pluto's demotion not a cause for classroom panic

13/May/2008 11:00AM
Analysts' opinions on stocks in the news Tuesday

13/May/2008 9:37AM
Investors took their cues from a weak sales forecast by Wal-Mart and ignored better than expected retail data

13/May/2008 8:41AM
Tuesday's stocks in the news

12/May/2008 11:09PM
As traditional sources such as banks and government agencies pull back, peer-to-peer lending is entering the student loan market

12/May/2008 11:01PM
S&amp;P likes the Mexican homebuilder's steady revenue growth and conservative lending practices, and ranks the shares strong buy

Copyright © 2006 Rootio Ltd. All rights reserved.